Clinical Trials for Cervical Cancer

Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic NSCLC (EGFR/ALK–, PD-L1 TPS ≥50%), HNSCC (PD-L1 CPS ≥20), or melanoma (any PD-L1/BRAF) who are either ICI-naive or have progressed on prior PD‑1/PD‑L1 therapy receive pembrolizumab plus CJRB‑101, an oral live biotherapeutic (Leuconostoc mesenteroides) designed to modulate the tumor-immune microenvironment (macrophage repolarization, APC activation, ↑CD8+ infiltration) to enhance PD‑1 blockade. Key exclusions include EGFR/ALK+ NSCLC, nasopharyngeal carcinoma, uncontrolled brain mets, significant autoimmune disease/IBD, key infections, and inability to take oral capsules.

ClinicalTrials.gov ID: NCT05877430

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable, recurrent, or metastatic androgen receptor–positive salivary gland carcinoma (ECOG 0–1), including previously treated patients without prior ADT or checkpoint inhibitors, receive goserelin (GnRH agonist ADT) plus pembrolizumab (anti–PD-1) until progression or toxicity. Stable, treated brain metastases are allowed; key exclusions include active autoimmune disease requiring systemic therapy and significant immunosuppression.

ClinicalTrials.gov ID: NCT03942653

A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent/metastatic HNSCC (oropharynx, oral cavity, hypopharynx, or larynx) receive subcutaneous amivantamab—an EGFR/MET bispecific antibody—either as monotherapy or combined with pembrolizumab, paclitaxel, or pembrolizumab plus carboplatin, with cohort-specific HPV/p16 requirements and prior therapy allowances. The study assesses safety and antitumor activity across these regimens and establishes the recommended dose for the amivantamab-paclitaxel combination.

ClinicalTrials.gov ID: NCT06385080

Restoration of Radioiodine Uptake with Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer: a Phase 2 Study Performed in Collaboration with the International Thyroid Oncology Group (ITOG)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: RET fusion–positive, radioiodine-refractory differentiated thyroid cancer (adolescents ≥12 and adults) with metastatic/unresectable disease, limited prior therapy, and no prior RET TKI receive a short selpercatinib lead-in (selective RET kinase inhibitor) to restore radioiodine uptake followed by therapeutic I-131 under rhTSH, with an option for a second selpercatinib/I-131 course if uptake is restored. Key allowances include treated/stable brain metastases; exclusions include QT-prolonging risks and recent I-131.

ClinicalTrials.gov ID: NCT05668962

Administration of T Cells Expressing Chondroitin-Sulfate-Proteoglycan-4 Specific Chimeric Antigen Receptors (CAR) in Subjects With Head and Neck Squamous Cell Carcinoma (HNSCC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated recurrent/metastatic HNSCC (oral cavity, oropharynx, hypopharynx, larynx; KPS >60%) receive lymphodepleting cyclophosphamide/fludarabine followed by a single infusion of autologous iC9.CAR-CSPG4 T cells, an anti-CSPG4 CAR T product with an inducible caspase-9 safety switch for potential rapid ablation. Key exclusions include significant cardiovascular disease, recent stroke/TIA, and severe hypersensitivity to cyclophosphamide or fludarabine.

ClinicalTrials.gov ID: NCT06096038

An Open Label Phase II Trial Evaluating the Efficacy of Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic, RAI‑refractory differentiated thyroid cancer with RECIST-defined progression (ECOG 0–2) receive oral cyclophosphamide (intermittent low-dose) plus sirolimus daily. Sirolimus targets mTORC1 (PI3K/AKT/mTOR pathway inhibition), aiming for antiproliferative/antiangiogenic synergy with metronomic cyclophosphamide; excludes prior mTOR inhibitor exposure and requires available prior NGS.

ClinicalTrials.gov ID: NCT03099356

Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced unresectable or metastatic/oligometastatic (≤5 sites) HPV+ or HPV− head and neck squamous cell carcinoma with measurable TROP2 IHC 2+/3+ disease and ECOG 0–1 receive lymphodepleting fludarabine/cyclophosphamide followed by allogeneic cord blood–derived TROP2-directed CAR-NK cells engineered to express IL-15 (to support NK persistence) and with TGFBR2 knockout (to resist TGF-β–mediated immunosuppression). Patients are treated in cohorts with CAR-NK therapy alone versus with preconditioning radiation/SBRT bridging when feasible (often leaving one measurable lesion unirradiated for response assessment).

ClinicalTrials.gov ID: NCT07101432

Feasibility Trial of Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with HPV-negative, PD-L1 CPS >1 recurrent/metastatic head and neck squamous cell carcinoma, no prior checkpoint inhibitor therapy, and an ultrasound- and biopsy-accessible measurable lesion. Patients receive pembrolizumab, an anti–PD-1 antibody, with Definity perflutren microbubbles and tumor-directed ultrasound-induced cavitation intended to enhance intratumoral drug delivery and immune response.

ClinicalTrials.gov ID: NCT07501650

An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Tislelizumab Plus Chemotherapy in a First-Line Setting for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in US Racial and Ethnic Minority Patients

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults from US racial or ethnic minority populations with previously untreated PD-L1-positive, locally advanced unresectable or metastatic HER2-negative gastric/gastroesophageal adenocarcinoma or esophageal squamous cell carcinoma receive tislelizumab, an anti–PD-1 antibody, plus first-line platinum/fluoropyrimidine chemotherapy (FOLFOX, CAPOX, or cisplatin/5-FU depending on tumor type).

ClinicalTrials.gov ID: NCT07554521

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial involves adults with unresectable or metastatic advanced solid tumors who have progressed on prior treatments or are candidates for pembrolizumab, combining pembrolizumab, which targets the PD-1 receptor to enhance immune response, with a personalized neoantigen peptide vaccine designed to stimulate an individualized immune attack against tumor-associated proteins.

ClinicalTrials.gov ID: NCT05269381